Weight and Metabolic Outcomes in Naïve HIV Patients Treated with Integrase Inhibitor-Based Antiretroviral Therapy: A Systematic Review and Meta-Analysis
出版年份 2023 全文链接
标题
Weight and Metabolic Outcomes in Naïve HIV Patients Treated with Integrase Inhibitor-Based Antiretroviral Therapy: A Systematic Review and Meta-Analysis
作者
关键词
-
出版物
Journal of Clinical Medicine
Volume 12, Issue 11, Pages 3644
出版商
MDPI AG
发表日期
2023-05-25
DOI
10.3390/jcm12113644
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South Africa
- (2023) Alana T. Brennan et al. EClinicalMedicine
- Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis
- (2022) Ruojing Bai et al. BMC INFECTIOUS DISEASES
- Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug
- (2022) Nikos Pantazis et al. Viruses-Basel
- Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents
- (2021) Dathan M. Byonanebye AIDS
- Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: Republication
- (2021) Shahini Shah et al. Current Opinion in HIV and AIDS
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naïve and Switch Scenarios in HIV-Infected Patients
- (2021) Maria Saumoy et al. Journal of Clinical Medicine
- Integrase Inhibitor Use Associated with Weight Gain in Women and Incident Diabetes Mellitus
- (2021) Archana Asundi et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Obesity and Weight Gain in Persons with HIV
- (2020) Samuel S. Bailin et al. Current HIV/AIDS Reports
- CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
- (2020) Rulan Griesel et al. CLINICAL INFECTIOUS DISEASES
- HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety
- (2020) Kimberly K. Scarsi et al. DRUGS
- Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
- (2020) Willem D F Venter et al. Lancet HIV
- Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon
- (2020) Alexandra Calmy et al. Lancet HIV
- Cabotegravir is Not Associated with Weight Gain in HIV-uninfected Individuals in HPTN 077
- (2019) Raphael J Landovitz et al. CLINICAL INFECTIOUS DISEASES
- Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy
- (2019) Kassem Bourgi et al. CLINICAL INFECTIOUS DISEASES
- Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
- (2019) Paola Bagella et al. Infection and Drug Resistance
- Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
- (2019) Willem D.F. Venter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1
- (2019) NEW ENGLAND JOURNAL OF MEDICINE
- Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- (2019) Hans-Jürgen Stellbrink et al. Lancet HIV
- Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- (2019) David A Wohl et al. Lancet HIV
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
- (2019) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- Weight gain and integrase inhibitors
- (2019) Allison Ross Eckard et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
- (2018) Josep M Llibre et al. LANCET
- The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality
- (2018) Shejil Kumar et al. Frontiers in Endocrinology
- Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks
- (2015) Romina Quercia et al. CLINICAL DRUG INVESTIGATION
- Weight Change After Antiretroviral Therapy and Mortality
- (2015) B. Yuh et al. CLINICAL INFECTIOUS DISEASES
- On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
- (2015) Jean-Michel Molina et al. NEW ENGLAND JOURNAL OF MEDICINE
- Methods to estimate the between-study variance and its uncertainty in meta-analysis
- (2015) Areti Angeliki Veroniki et al. Research Synthesis Methods
- Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
- (2014) Bonaventura Clotet et al. LANCET
- Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO
- (2014) Jean-Michel Molina et al. Journal of the International AIDS Society
- A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) Jürgen K. Rockstroh et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
- (2013) Francois Raffi et al. LANCET
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- (2013) Sharon L. Walmsley et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation